Contineum Therapeutics (CTNM) EPS (Weighted Average and Diluted): 2023-2024
Historic EPS (Weighted Average and Diluted) for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to -$0.57.
- Contineum Therapeutics' EPS (Weighted Average and Diluted) fell 62.86% to -$0.57 in Q4 2024 from the same period last year, while for Dec 2024 it was -$2.28, marking a year-over-year change of. This contributed to the annual value of -$2.18 for FY2024, which is 2825.00% down from last year.
- According to the latest figures from Q4 2024, Contineum Therapeutics' EPS (Weighted Average and Diluted) is -$0.57, which was down 42.50% from -$0.40 recorded in Q3 2024.
- Contineum Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at -$0.10 during Q2 2023, with a 5-year trough of -$2.69 in Q3 2023.
- Over the past 2 years, Contineum Therapeutics' median EPS (Weighted Average and Diluted) value was -$0.49 (recorded in 2024), while the average stood at -$0.85.
- Examining YoY changes over the last 5 years, Contineum Therapeutics' EPS (Weighted Average and Diluted) showed a top increase of 85.13% in 2024 and a maximum decrease of 860.00% in 2024.
- Quarterly analysis of 2 years shows Contineum Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.35 in 2023, then slumped by 62.86% to -$0.57 in 2024.
- Its EPS (Weighted Average and Diluted) stands at -$0.57 for Q4 2024, versus -$0.40 for Q3 2024 and -$0.96 for Q2 2024.